Louis Ploth - Moleculin Biotech Independent Advisor
| MBRX Stock | USD 4.63 0.32 7.42% |
Insider
Louis Ploth is Independent Advisor of Moleculin Biotech
| Age | 70 |
| Address | 5300 Memorial Drive, Houston, TX, United States, 77007 |
| Phone | 713 300 5160 |
| Web | https://www.moleculin.com |
Moleculin Biotech Management Efficiency
The company has return on total asset (ROA) of (0.3873) % which means that it has lost $0.3873 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7607) %, meaning that it created substantial loss on money invested by shareholders. Moleculin Biotech's management efficiency ratios could be used to measure how well Moleculin Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.15 in 2024. Return On Capital Employed is likely to drop to -0.99 in 2024. At this time, Moleculin Biotech's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 12.8 M in 2024, whereas Total Assets are likely to drop slightly above 35.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Timothy Mayer | NextCure | 59 | |
| Roger Rush | Inhibikase TherapeuticsInc | N/A | |
| CPA CPA | NextCure | 61 | |
| Winston MBA | Pmv PharmaceuticalsInc | 48 | |
| Eduardo Marbn | Capricor Therapeutics | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| James JD | Allarity Therapeutics | 55 | |
| Peter MBA | Bio Path Holdings | 75 | |
| Alexander Klibanov | Pulmatrix | 74 | |
| Catherine Kelleher | Capricor Therapeutics | N/A | |
| Deepika PharmD | Pmv PharmaceuticalsInc | 47 | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| James Foster | Virax Biolabs Group | 39 | |
| Paul MD | AN2 Therapeutics | 54 | |
| Miles Nunn | Akari Therapeutics PLC | 55 | |
| Thomas Shenk | Pmv PharmaceuticalsInc | 77 | |
| Robert Westwood | Cyclacel Pharmaceuticals | 80 | |
| Dan Williams | Inhibikase TherapeuticsInc | N/A | |
| Melissa BradfordKlug | Akari Therapeutics PLC | 54 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Linda Marbn | Capricor Therapeutics | 61 | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 |
Moleculin Biotech Leadership Team
Elected by the shareholders, the Moleculin Biotech's board of directors comprises two types of representatives: Moleculin Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moleculin. The board's role is to monitor Moleculin Biotech's management team and ensure that shareholders' interests are well served. Moleculin Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moleculin Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Louis Ploth, Independent Advisor | ||
| Walter Klemp, Chairman, Founder | ||
| ScD MD, Senior Officer | ||
| Jonathan CPA, Executive CFO | ||
| Jacqueline Northcut, Consultant | ||
| Donald Picker, Chief Officer | ||
| Waldemar Priebe, Founding CoFounder | ||
| FACP MD, Chief Annamycin | ||
| MD FACP, Chief Annamycin | ||
| MBA MD, European Officer |
Moleculin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moleculin Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | (12.66 M) | ||||
| Shares Outstanding | 2.23 M | ||||
| Shares Owned By Insiders | 4.64 % | ||||
| Shares Owned By Institutions | 15.46 % | ||||
| Number Of Shares Shorted | 26.67 K | ||||
| Price To Earning | (3.81) X | ||||
| Price To Book | 0.40 X | ||||
| EBITDA | (29.5 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Moleculin Stock analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.15) | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.